<div id="readability-page-1"><p>AirSculpt Technologies (NASDAQ:AIRS - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01, FiscalAI reports. The company had revenue of $39.39 million during the quarter, compared to analyst estimates of $39.20 million. AirSculpt Technologies had a negative net margin of 7.68% and a negative return on equity of 5.01%.</p><div><p><span></span><span>Get <strong>AirSculpt Technologies</strong> alerts:</span></p></div><p>Here are the key takeaways from AirSculpt Technologies' conference call:</p><ul>   <li>AirSculpt reported <strong>$39.4 million</strong> in Q1 revenue (flat YoY) and achieved its first positive same-center sales in over two years, with same-store revenue up ~1% excluding London and a 19% sequential improvement.</li>   <li>Gross margin expanded to about <strong>60%</strong> (cost of services $15.6M), but adjusted EBITDA fell to <strong>$3.3 million</strong> (8.4% of revenue) as SG&amp;A rose roughly $0.8M due to deliberate marketing investments.</li>   <li>The balance sheet strengthened—cash of <strong>$16.7 million</strong>, $11 million of debt repaid in the quarter, gross debt of ~<strong>$46 million</strong>, leverage below 2.5x, and management is working on a term‑loan refinance while remaining in covenant compliance.</li>   <li>Management highlighted a large long‑term opportunity from <strong>GLP-1</strong> drug adoption (projected growth to 25M users by 2030) and is piloting skin‑tightening and skin‑removal procedures (150 skin excisions in Q1) that could unlock an estimated &gt;<strong>$100M</strong> across centers, though these services are not yet a meaningful revenue driver.</li>   <li>The company reaffirmed FY26 guidance of <strong>$151M–$157M</strong> in revenue and <strong>$15M–$17M</strong> in adjusted EBITDA, expects sequential improvement in Q2, and does not plan any de novo center openings in 2026 while prioritizing same‑center growth.</li> </ul><h2>AirSculpt Technologies Trading Down 0.8%</h2><p>Shares of AirSculpt Technologies stock traded down $0.03 during mid-day trading on Friday, hitting $3.43. The stock had a trading volume of 1,677,564 shares, compared to its average volume of 2,345,654. The company has a quick ratio of 0.55, a current ratio of 0.55 and a debt-to-equity ratio of 0.58. The firm has a market cap of $242.20 million, a P/E ratio of -18.05 and a beta of 1.99. The firm has a 50-day moving average of $2.57 and a two-hundred day moving average of $3.51. AirSculpt Technologies has a 12-month low of $1.51 and a 12-month high of $12.00. </p><h2>Insider Buying and Selling at AirSculpt Technologies</h2><p>In related news, major shareholder Jorey Chernett acquired 105,848 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was purchased at an average price of $2.43 per share, with a total value of $257,210.64. Following the transaction, the insider owned 6,592,059 shares of the company's stock, valued at approximately $16,018,703.37. This trade represents a 1.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 810,150 shares of company stock worth $1,987,624. Company insiders own  44.60% of the company's stock. </p><h2>Hedge Funds Weigh In On AirSculpt Technologies</h2><p>A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of  AirSculpt Technologies during the 4th quarter worth approximately $30,000.  XTX Topco Ltd boosted its position in shares of  AirSculpt Technologies by 265.2% during the 4th quarter. XTX Topco Ltd now owns 179,813 shares of the company's stock worth $356,000 after purchasing an additional 130,581 shares during the period.  Tudor Investment Corp ET AL purchased a new position in shares of  AirSculpt Technologies during the 4th quarter worth approximately $219,000.  Saba Capital Management L.P. purchased a new position in shares of  AirSculpt Technologies during the 4th quarter worth approximately $620,000.  Finally, Millennium Management LLC purchased a new position in shares of  AirSculpt Technologies during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own  91.54% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>Separately, Wall Street Zen raised shares of AirSculpt Technologies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, April 5th. One investment analyst  has rated the stock with a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, AirSculpt Technologies currently has an average rating of &#34;Reduce&#34; and a consensus price target of $6.00.</p><p><b>Read Our Latest Stock Analysis on AIRS</b></p><h2>AirSculpt Technologies Company Profile</h2> (Get Free Report)<p>AirSculpt Technologies, Inc <span>NASDAQ: AIRS<span></span></span> is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction. </p><p>Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than AirSculpt Technologies</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUlSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUlSUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AirSculpt Technologies Right Now?</h2><p>Before you consider AirSculpt Technologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AirSculpt Technologies wasn't on the list.</p><p>While AirSculpt Technologies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AIRS

<p>AirSculpt Technologies (NASDAQ:AIRS) reported quarterly earnings of ($0.01) per share, surpassing estimates of ($0.02) by $0.01. Revenue reached $39.39 million, exceeding expectations of $39.20 million. The company noted a negative net margin of 7.68% and a negative return on equity of 5.01%. Management highlighted growth opportunities from GLP-1 drug adoption and plans for skin-tightening procedures. The company reaffirmed FY26 revenue guidance of $151M–$157M. Shares traded down 0.8% to $3.43, with hedge funds holding 91.54% of the stock. Analysts have a consensus price target of $6.00.</p>

AirSculpt Technologies (NASDAQ:AIRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS